Biopharmaceutical start-up BioAge Labs is developing a weight loss drug for older adults known as azelaprag, which is intended to be taken orally along with other weight loss drugs. According to ...

Obesity drug developer BioAge Labs (BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at ...

BioAge shifted the drug’s focus to obesity after encouraging preclinical tests of the molecule dosed in combination with Lilly’s Zepbound showed greater weight loss than Zepbound alone.

(Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor ...

BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 A scientist in a lab coat analyzing samples from a petri dish, studying the effects of a potential drug ...

BioAge has shown that in preclinical obesity models, APJ agonism can approximately double the weight loss induced by GLP-1 receptor agonists while restoring healthy body composition and improving ...

BioAge advances obesity drug into clinical trials. ... demonstrating weight loss both as a standalone treatment and when combined with GLP-1 receptor agonists.

Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss space. The Bay Area biotech has entered an option agreement with Chinese ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.